The selection process on which IND to get initial approval for Iclusig must have been interesting. The potential revenues from these other INDs are huge, much larger than CML/GIST.
Should many of the INDs pan out, we could see Revs similar to the growth of Avastin + Gleevec/Tas.
jaybe, you post unique, important information. Great posts for us all. Thank you.